Chimerix Hisse

Chimerix PEG

Delisted·17 Nis 2025

Chimerix (CMRX) öğesinin PEG Oranı (Fiyat/Kâr-Büyüme) değeri 26 Ağu 2026 itibarıyla.

PEG

0,00

Son güncelleme:

Chimerix öğesinin PEG Oranı (Fiyat/Kâr-Büyüme) değeri 2026 0,00 dir. Chimerix öğesinin PEG Oranı (Fiyat/Kâr-Büyüme) değeri 2025 0,00 idi. % daha düşük önceki yıla kıyasla azalmaktadır.
Access this data via the Eulerpool API

Chimerix Hisse senedi analizi

Chimerix ne yapar? Chimerix Inc is a biopharmaceutical company focused on the development of antiviral drugs. The company was founded in 2002 and is headquartered in Durham, North Carolina. The history of Chimerix dates back to the research of Dr. George Painter, a renowned scientist in the field of antiviral therapy. He discovered that a certain group of molecules, known as nucleoside analogues, have antiviral properties. The idea was to use these molecules as a starting point for the development of drugs that specifically target viruses. The core idea of Chimerix was to create a new business model that is different from traditional pharmaceutical companies. Instead of focusing on the lengthy and costly development of new compounds, the company wanted to utilize existing molecules and create new drugs through targeted modifications. This approach was not only expected to be faster and cost-effective but also to offer higher chances of success. Chimerix is divided into several business segments. The most important segment is antiviral therapy, where the company focuses on developing drugs against various viruses such as Cytomegalovirus (CMV), Adenovirus, and Herpesvirus. Another business segment of Chimerix is oncology. Here, the company also relies on modifying existing compounds to develop new and effective cancer drugs. One promising molecule currently being developed is Brincidofovir, which not only has antiviral properties but also possesses antitumor properties. In addition to drug development, Chimerix also offers support for clinical trials. The company collaborates with various research institutions and biopharmaceutical companies to test the efficacy and safety of new compounds. The most well-known product of Chimerix is Brincidofovir. This antiviral drug is currently being tested in clinical trials and has the potential to be used against a range of viruses. Its use is particularly promising in patients undergoing immunosuppressive therapy, such as those after a stem cell transplant. Chimerix aims to develop innovative and effective drugs that help patients overcome serious diseases. With its unique business model and close collaboration with the research community, the company has already made promising progress and is an important player in the field of antiviral therapy and oncology. Chimerix, Eulerpool'daki en popüler şirketlerden biridir.

Chimerix hisse senedi hakkında sık sorulan sorular

Eulerpool'da PEG Oranı (Fiyat/Kâr-Büyüme) öğesinin Chimerix değerinin 2006'dan itibaren tam tarihsel gelişimini bulabilirsiniz — yıllık değerler, grafikler ve ayrıntılı analiz ile.

PEG oranı, FD/K oranını beklenen kâr büyüme oranına göre ayarlar. 1'in altında bir PEG, büyüme potansiyeline kıyasla düşük değerli hisseyi gösterebilir.

PEG = F/D Oranı / Beklenen Yıllık EPS Büyüme Oranı

PEG Oranı (Fiyat/Kâr-Büyüme)'nin değerini değerlendirmek için, aynı endüstri ve sektördeki emsalleriyle karşılaştırması önemlidir. Eulerpool'da PEG Oranı (Fiyat/Kâr-Büyüme) için doğrudan endüstri karşılaştırmaları bulabilirsiniz.

İyi bir değeri endüstriye ve şirketin aşamasına göre değişir. Eulerpool'da, PEG Oranı (Fiyat/Kâr-Büyüme)'nin Chimerix değerini sektör emsalleriyle ve endüstri ortalamasıyla karşılaştırarak cazip olup olmadığını değerlendirebilirsiniz.

Access this data via the Eulerpool API

Değerleme — Chimerix

Tüm Kilit Metrikler — Chimerix